Sequenom Inc. (NASDAQ:SQNM)’s shares gained 1.21% to $3.77. Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (SQNM), a life sciences company providing innovative genetic analysis solutions, on June 19 announced that Nicox’s subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene™ portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual’s risk for advanced age-related macular degeneration (AMD).
Exelixis, Inc. (NASDAQ:EXEL)’s shares decreased 2.40% to $3.25. The 52 week trading range for the company is $3.02 – $8.41. The shares of the company fell 31% in the last one year. The company is a biotechnology company engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing its resources and development efforts on cabozantinib (XL184). It also has a portfolio of other compounds. Cabozantinib is the inhibitor of MET in clinical development and is being evaluated in a development program encompassing multiple cancer indications.
Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX)’s shares decreased 0.47% to $4.26. The company on June 11 announced that NASDAQ has halted trading of the company’s common stock.
The U.S. Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee is meeting today and tomorrow, June 11 and 12, to discuss the potential cardiovascular risk associated with products in the class of peripherally-acting opioid receptor antagonists and the necessity, timing, design and size of cardiovascular outcomes trials to support approval of products in the class for the proposed indication of opioid-induced constipation in patients taking opioids for chronic pain.